Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-11-26

AUTHORS

Martin Rowland, Alessandro Cavecchi, Frank Thielmann, Janusz Kulon, Jag Shur, Robert Price

ABSTRACT

PurposeTo measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide™ 250 μg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 μg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 μg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI).MethodsFive successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios.ResultsThe ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was greater in magnitude than the positively charged particles.ConclusionsThe bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process. More... »

PAGES

15

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11095-018-2544-9

DOI

http://dx.doi.org/10.1007/s11095-018-2544-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110203303

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30478630


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aerosols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemistry, Pharmaceutical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Equipment Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluticasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluticasone-Salmeterol Drug Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metered Dose Inhalers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Particle Size", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Powders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salmeterol Xinafoate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Static Electricity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surface Properties", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Suspensions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Technology, Pharmaceutical", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd, Discovery Park House, Sandwich, CT13 9NJ, Kent, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK", 
            "Pfizer Ltd, Discovery Park House, Sandwich, CT13 9NJ, Kent, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rowland", 
        "givenName": "Martin", 
        "id": "sg:person.01314137531.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314137531.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chiesi Farmaceutici S.p.A, Via Palermo, 26 A, 43122, Parma, Italy", 
          "id": "http://www.grid.ac/institutes/grid.467287.8", 
          "name": [
            "Novartis Pharma AG, Forum 1, Novartis Campus, 4056, Basel, CH, Switzerland", 
            "Chiesi Farmaceutici S.p.A, Via Palermo, 26 A, 43122, Parma, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cavecchi", 
        "givenName": "Alessandro", 
        "id": "sg:person.014274754726.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014274754726.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma AG, Forum 1, Novartis Campus, 4056, Basel, CH, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Forum 1, Novartis Campus, 4056, Basel, CH, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thielmann", 
        "givenName": "Frank", 
        "id": "sg:person.0754575565.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754575565.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Computing, Engineering and Science, University of South Wales, CF37 1DL, Pontypridd, UK", 
          "id": "http://www.grid.ac/institutes/grid.410658.e", 
          "name": [
            "Faculty of Computing, Engineering and Science, University of South Wales, CF37 1DL, Pontypridd, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kulon", 
        "givenName": "Janusz", 
        "id": "sg:person.0643742600.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643742600.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK", 
          "id": "http://www.grid.ac/institutes/grid.7340.0", 
          "name": [
            "Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shur", 
        "givenName": "Jag", 
        "id": "sg:person.0777215157.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777215157.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK", 
          "id": "http://www.grid.ac/institutes/grid.7340.0", 
          "name": [
            "Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Price", 
        "givenName": "Robert", 
        "id": "sg:person.0737612023.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737612023.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11095-015-1786-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032990646", 
          "https://doi.org/10.1007/s11095-015-1786-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-009-9979-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011127062", 
          "https://doi.org/10.1007/s11095-009-9979-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-008-9761-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008431998", 
          "https://doi.org/10.1007/s11095-008-9761-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-008-9651-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006231531", 
          "https://doi.org/10.1007/s11095-008-9651-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-26", 
    "datePublishedReg": "2018-11-26", 
    "description": "PurposeTo measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide\u2122 250\u00a0\u03bcg Evohaler, containing fluticasone propionate (FP), Serevent\u2122 25\u00a0\u03bcg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide\u2122 250/25\u00a0\u03bcg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI).MethodsFive successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios.ResultsThe ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide\u2122 and Seretide\u2122 MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent\u2122 exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide\u2122 exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent\u2122 was greater in magnitude than the positively charged particles.ConclusionsThe bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11095-018-2544-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "commercial MDI products", 
      "SX particles", 
      "bipolar charge distribution", 
      "charge distribution", 
      "measurement apparatus", 
      "successive shots", 
      "particles", 
      "stage mass", 
      "Serevent", 
      "aerosol particles", 
      "FP particles", 
      "positive charge", 
      "charge", 
      "aerosolisation process", 
      "aerosol cloud", 
      "crystals", 
      "ice crystals", 
      "magnitude", 
      "shot", 
      "cloud", 
      "measurements", 
      "electrostatic precipitator", 
      "salmeterol xinafoate", 
      "Flixotide", 
      "Evohaler", 
      "ratio", 
      "mass", 
      "quantity", 
      "MDI products", 
      "apparatus", 
      "distribution", 
      "aerosols", 
      "Next Generation Impactor", 
      "propellants", 
      "precipitator", 
      "impactor", 
      "fluticasone propionate", 
      "process", 
      "Seretide", 
      "presence", 
      "MDI", 
      "dose inhaler", 
      "doses", 
      "suspension", 
      "stage 2", 
      "inhaler", 
      "greater quantities", 
      "products", 
      "PurposeTo", 
      "propionate", 
      "purpose", 
      "impactor stage masses", 
      "commercial Flixotide", 
      "xinafoate", 
      "combination Seretide", 
      "bipolar charge measurement apparatus", 
      "charge measurement apparatus", 
      "Generation Impactor", 
      "MethodsFive successive shots", 
      "respective MDIs", 
      "bp-NGI", 
      "whole ISM doses", 
      "ISM doses", 
      "standard NGI", 
      "SX aerosol", 
      "ConclusionsThe bp-NGI", 
      "Fine Particle Aerosol Clouds", 
      "Particle Aerosol Clouds", 
      "Commercial PMDI Suspensions", 
      "PMDI Suspensions", 
      "Bipolar Next Generation Impactor"
    ], 
    "name": "Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)", 
    "pagination": "15", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110203303"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11095-018-2544-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30478630"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11095-018-2544-9", 
      "https://app.dimensions.ai/details/publication/pub.1110203303"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_778.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11095-018-2544-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11095-018-2544-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11095-018-2544-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11095-018-2544-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11095-018-2544-9'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      22 PREDICATES      115 URIs      103 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11095-018-2544-9 schema:about N0ef9e6cf32f740b9ba76f1c2a467958b
2 N1693e515b9864ca5a3f52692d83341d5
3 N2aacf4d2cda04cd1871db8728e333d6a
4 N3768f7e10bb54618a9bfd530c1aaa905
5 N44146e7fe68645aebe0ab4e23c9d93fd
6 N59cbd5020cc84cf2a233b282d4b2957c
7 N6117de2e4dca4b4197ffcb8b6e0b07ba
8 N6ae84a7a0af04a2893e8028a10acfaa0
9 N8605b3fdc81f45d2bfc8101bdf1239a8
10 N8a3a39afeeba446cb05d02074acdc106
11 N9c63ad90feb3472da59fcb861c876001
12 Naf8623bfef784f18ad7ff758173a64ed
13 Nc4821811894e4c93acc1759f369ac7e0
14 Nff4267a606314e37a3298144c38d6117
15 anzsrc-for:11
16 anzsrc-for:1115
17 schema:author N425e30e4286349c9bcb4580bf034a96c
18 schema:citation sg:pub.10.1007/s11095-008-9651-y
19 sg:pub.10.1007/s11095-008-9761-6
20 sg:pub.10.1007/s11095-009-9979-y
21 sg:pub.10.1007/s11095-015-1786-z
22 schema:datePublished 2018-11-26
23 schema:datePublishedReg 2018-11-26
24 schema:description PurposeTo measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from commercial Flixotide™ 250 μg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 μg Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 μg (FP/SX) Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly connected below Stage 2 of a Next Generation Impactor (NGI).MethodsFive successive shots of the respective MDIs were actuated through the bp-NGI. The whole ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios.ResultsThe ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was greater in magnitude than the positively charged particles.ConclusionsThe bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs may have been enhanced by the presence of charged ice crystals formed from the propellant during the aerosolisation process.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N2dc63abdc1c444febe43db71097964fe
29 Na5f739abfe214c64892daeb2aace6f88
30 sg:journal.1094644
31 schema:keywords Bipolar Next Generation Impactor
32 Commercial PMDI Suspensions
33 ConclusionsThe bp-NGI
34 Evohaler
35 FP particles
36 Fine Particle Aerosol Clouds
37 Flixotide
38 Generation Impactor
39 ISM doses
40 MDI
41 MDI products
42 MethodsFive successive shots
43 Next Generation Impactor
44 PMDI Suspensions
45 Particle Aerosol Clouds
46 PurposeTo
47 SX aerosol
48 SX particles
49 Seretide
50 Serevent
51 aerosol cloud
52 aerosol particles
53 aerosolisation process
54 aerosols
55 apparatus
56 bipolar charge distribution
57 bipolar charge measurement apparatus
58 bp-NGI
59 charge
60 charge distribution
61 charge measurement apparatus
62 cloud
63 combination Seretide
64 commercial Flixotide
65 commercial MDI products
66 crystals
67 distribution
68 dose inhaler
69 doses
70 electrostatic precipitator
71 fluticasone propionate
72 greater quantities
73 ice crystals
74 impactor
75 impactor stage masses
76 inhaler
77 magnitude
78 mass
79 measurement apparatus
80 measurements
81 particles
82 positive charge
83 precipitator
84 presence
85 process
86 products
87 propellants
88 propionate
89 purpose
90 quantity
91 ratio
92 respective MDIs
93 salmeterol xinafoate
94 shot
95 stage 2
96 stage mass
97 standard NGI
98 successive shots
99 suspension
100 whole ISM doses
101 xinafoate
102 schema:name Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)
103 schema:pagination 15
104 schema:productId Nb65d9038c4434e8fb2966711c501ee4c
105 Nbd3eb3b863b04838b93766afdc6108de
106 Nfa35f3fc8c6d46f6b3cce9bc595d1cb2
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110203303
108 https://doi.org/10.1007/s11095-018-2544-9
109 schema:sdDatePublished 2021-12-01T19:42
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nb7833147ea6e496582c62ba6f12606cf
112 schema:url https://doi.org/10.1007/s11095-018-2544-9
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N0ef9e6cf32f740b9ba76f1c2a467958b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Powders
118 rdf:type schema:DefinedTerm
119 N1693e515b9864ca5a3f52692d83341d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Technology, Pharmaceutical
121 rdf:type schema:DefinedTerm
122 N2aacf4d2cda04cd1871db8728e333d6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Surface Properties
124 rdf:type schema:DefinedTerm
125 N2dc63abdc1c444febe43db71097964fe schema:issueNumber 1
126 rdf:type schema:PublicationIssue
127 N3768f7e10bb54618a9bfd530c1aaa905 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Metered Dose Inhalers
129 rdf:type schema:DefinedTerm
130 N425e30e4286349c9bcb4580bf034a96c rdf:first sg:person.01314137531.35
131 rdf:rest N9f0af7c064864c9e9cb10b74a34cb1c5
132 N44146e7fe68645aebe0ab4e23c9d93fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Chemistry, Pharmaceutical
134 rdf:type schema:DefinedTerm
135 N59cbd5020cc84cf2a233b282d4b2957c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Administration, Inhalation
137 rdf:type schema:DefinedTerm
138 N5c962eab73ab4f60823e5b17b201f060 rdf:first sg:person.0643742600.22
139 rdf:rest N98b5a4c11b1f42fe819dc3a567c53d67
140 N6117de2e4dca4b4197ffcb8b6e0b07ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Fluticasone-Salmeterol Drug Combination
142 rdf:type schema:DefinedTerm
143 N6ae84a7a0af04a2893e8028a10acfaa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Suspensions
145 rdf:type schema:DefinedTerm
146 N744ae4f7f8cd49d98ec2636e0c92aae4 rdf:first sg:person.0754575565.65
147 rdf:rest N5c962eab73ab4f60823e5b17b201f060
148 N8605b3fdc81f45d2bfc8101bdf1239a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Salmeterol Xinafoate
150 rdf:type schema:DefinedTerm
151 N8a3a39afeeba446cb05d02074acdc106 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Equipment Design
153 rdf:type schema:DefinedTerm
154 N98b5a4c11b1f42fe819dc3a567c53d67 rdf:first sg:person.0777215157.90
155 rdf:rest Na5f3e47e8422421fb86aa7f5fa416dd9
156 N9c63ad90feb3472da59fcb861c876001 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Fluticasone
158 rdf:type schema:DefinedTerm
159 N9f0af7c064864c9e9cb10b74a34cb1c5 rdf:first sg:person.014274754726.50
160 rdf:rest N744ae4f7f8cd49d98ec2636e0c92aae4
161 Na5f3e47e8422421fb86aa7f5fa416dd9 rdf:first sg:person.0737612023.23
162 rdf:rest rdf:nil
163 Na5f739abfe214c64892daeb2aace6f88 schema:volumeNumber 36
164 rdf:type schema:PublicationVolume
165 Naf8623bfef784f18ad7ff758173a64ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Static Electricity
167 rdf:type schema:DefinedTerm
168 Nb65d9038c4434e8fb2966711c501ee4c schema:name doi
169 schema:value 10.1007/s11095-018-2544-9
170 rdf:type schema:PropertyValue
171 Nb7833147ea6e496582c62ba6f12606cf schema:name Springer Nature - SN SciGraph project
172 rdf:type schema:Organization
173 Nbd3eb3b863b04838b93766afdc6108de schema:name pubmed_id
174 schema:value 30478630
175 rdf:type schema:PropertyValue
176 Nc4821811894e4c93acc1759f369ac7e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Particle Size
178 rdf:type schema:DefinedTerm
179 Nfa35f3fc8c6d46f6b3cce9bc595d1cb2 schema:name dimensions_id
180 schema:value pub.1110203303
181 rdf:type schema:PropertyValue
182 Nff4267a606314e37a3298144c38d6117 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Aerosols
184 rdf:type schema:DefinedTerm
185 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
186 schema:name Medical and Health Sciences
187 rdf:type schema:DefinedTerm
188 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
189 schema:name Pharmacology and Pharmaceutical Sciences
190 rdf:type schema:DefinedTerm
191 sg:journal.1094644 schema:issn 0724-8741
192 1573-904X
193 schema:name Pharmaceutical Research
194 schema:publisher Springer Nature
195 rdf:type schema:Periodical
196 sg:person.01314137531.35 schema:affiliation grid-institutes:grid.418566.8
197 schema:familyName Rowland
198 schema:givenName Martin
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314137531.35
200 rdf:type schema:Person
201 sg:person.014274754726.50 schema:affiliation grid-institutes:grid.467287.8
202 schema:familyName Cavecchi
203 schema:givenName Alessandro
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014274754726.50
205 rdf:type schema:Person
206 sg:person.0643742600.22 schema:affiliation grid-institutes:grid.410658.e
207 schema:familyName Kulon
208 schema:givenName Janusz
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643742600.22
210 rdf:type schema:Person
211 sg:person.0737612023.23 schema:affiliation grid-institutes:grid.7340.0
212 schema:familyName Price
213 schema:givenName Robert
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737612023.23
215 rdf:type schema:Person
216 sg:person.0754575565.65 schema:affiliation grid-institutes:grid.419481.1
217 schema:familyName Thielmann
218 schema:givenName Frank
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754575565.65
220 rdf:type schema:Person
221 sg:person.0777215157.90 schema:affiliation grid-institutes:grid.7340.0
222 schema:familyName Shur
223 schema:givenName Jag
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777215157.90
225 rdf:type schema:Person
226 sg:pub.10.1007/s11095-008-9651-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1006231531
227 https://doi.org/10.1007/s11095-008-9651-y
228 rdf:type schema:CreativeWork
229 sg:pub.10.1007/s11095-008-9761-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008431998
230 https://doi.org/10.1007/s11095-008-9761-6
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/s11095-009-9979-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1011127062
233 https://doi.org/10.1007/s11095-009-9979-y
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s11095-015-1786-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1032990646
236 https://doi.org/10.1007/s11095-015-1786-z
237 rdf:type schema:CreativeWork
238 grid-institutes:grid.410658.e schema:alternateName Faculty of Computing, Engineering and Science, University of South Wales, CF37 1DL, Pontypridd, UK
239 schema:name Faculty of Computing, Engineering and Science, University of South Wales, CF37 1DL, Pontypridd, UK
240 rdf:type schema:Organization
241 grid-institutes:grid.418566.8 schema:alternateName Pfizer Ltd, Discovery Park House, Sandwich, CT13 9NJ, Kent, UK
242 schema:name Pfizer Ltd, Discovery Park House, Sandwich, CT13 9NJ, Kent, UK
243 Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK
244 rdf:type schema:Organization
245 grid-institutes:grid.419481.1 schema:alternateName Novartis Pharma AG, Forum 1, Novartis Campus, 4056, Basel, CH, Switzerland
246 schema:name Novartis Pharma AG, Forum 1, Novartis Campus, 4056, Basel, CH, Switzerland
247 rdf:type schema:Organization
248 grid-institutes:grid.467287.8 schema:alternateName Chiesi Farmaceutici S.p.A, Via Palermo, 26 A, 43122, Parma, Italy
249 schema:name Chiesi Farmaceutici S.p.A, Via Palermo, 26 A, 43122, Parma, Italy
250 Novartis Pharma AG, Forum 1, Novartis Campus, 4056, Basel, CH, Switzerland
251 rdf:type schema:Organization
252 grid-institutes:grid.7340.0 schema:alternateName Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK
253 schema:name Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology, University of Bath, BA2 7AY, Bath, UK
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...